Short-Acting Insulin Market ANALYSE DE LA TAILLE ET DU PARTAGE - TENDANCES DE CROISSANCE ET PRÉVISIONS (2024 - 2031)
Short-Acting Insulin Market is segmented By Type (Insulin Lispro, Insulin Aspart, Insulin Glulisine), By Indication (Type 1 Diabetes, Type 2 Diabetes), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Short-Acting Insulin Market Size
Taille du Marché en USD Bn
TCAC5.1%
| Période d'Étude | 2024 - 2031 |
| Année de Base de l'Estimation | 2023 |
| TCAC | 5.1% |
| Concentration du Marché | High |
| Principaux Acteurs | Eli Lilly and Company, Novo Nordisk, Sanofi, Biocon, Adocia and Among Others. |
please let us know !
Short-Acting Insulin Market Analysis
The short-acting insulin market is estimated to be valued at USD 9.5 Bn in 2024 and is expected to reach USD 13.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2031. The market is expected to grow steadily over the forecast period due to the increasing prevalence of diabetes globally and rise in healthcare expenditure.
The short-acting insulin market is expected to witness substantial growth over the coming years. Key growth factors for the market include the rising incidence of diabetes, growing geriatric population, and increasing healthcare spending.
Moreover, the development of cost-effective biosimilar insulin drugs and the introduction of innovative fast-acting insulin analogs are also contributing to market growth. However, strict regulations for the approval of insulin drugs and the availability of alternative treatment options for diabetes may hamper market growth during the forecast period. Overall, increasing diabetes prevalence and improved access to diagnosis and treatment define the future growth trajectory of the short-acting insulin market.